
Kelun-Biotech first to bag TROP2 approval in lung cancer
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to regulatory approval in lung cancer, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The MSD-partnered ADC has been …